Your browser doesn't support javascript.
loading
Outcomes after Surgical Treatment of Oesophagogastric Cancer with Synchronous Liver Metastases: A Multicentre Retrospective Cohort Study.
van Hootegem, Sander J M; de Pasqual, Carlo A; Giacopuzzi, Simone; Van Daele, Elke; Vanommeslaeghe, Hanne; Moons, Johnny; Nafteux, Philippe; van der Sluis, Pieter C; Lagarde, Sjoerd M; Wijnhoven, Bas P L.
Afiliación
  • van Hootegem SJM; Department of Surgery, Erasmus University Medical Center, 3000 CA Rotterdam, The Netherlands.
  • de Pasqual CA; General and Upper GI Surgery Division, University Hospital of Verona, 37134 Verona, Italy.
  • Giacopuzzi S; General and Upper GI Surgery Division, University Hospital of Verona, 37134 Verona, Italy.
  • Van Daele E; Department of Gastrointestinal Surgery, Ghent University Hospital, B-9000 Ghent, Belgium.
  • Vanommeslaeghe H; Department of Gastrointestinal Surgery, Ghent University Hospital, B-9000 Ghent, Belgium.
  • Moons J; Department of Thoracic Surgery, University Hospitals Leuven, 3000 Leuven, Belgium.
  • Nafteux P; Department of Thoracic Surgery, University Hospitals Leuven, 3000 Leuven, Belgium.
  • van der Sluis PC; Department of Surgery, Erasmus University Medical Center, 3000 CA Rotterdam, The Netherlands.
  • Lagarde SM; Department of Surgery, Erasmus University Medical Center, 3000 CA Rotterdam, The Netherlands.
  • Wijnhoven BPL; Department of Surgery, Erasmus University Medical Center, 3000 CA Rotterdam, The Netherlands.
Cancers (Basel) ; 16(4)2024 Feb 16.
Article en En | MEDLINE | ID: mdl-38398190
ABSTRACT
Approximately 10-12% of patients with oesophageal or gastric cancer (OGC) present with oligometastatic disease at diagnosis. It remains unclear if there is a role for radical surgery in these patients. We aimed to assess the outcomes of OGC patients who underwent simultaneous treatment for the primary tumour and synchronous liver metastases. Patients with OGC who underwent surgical treatment between 2008 and 2020 for the primary tumour and up to five synchronous liver metastases aiming for complete tumour removal or ablation (i.e., no residual tumour) were identified from four institutional databases. The primary outcome was overall survival (OS), calculated with the Kaplan-Meier method. Secondary outcomes were disease-free survival and postoperative outcomes. Thirty-one patients were included, with complete follow-up data for 30 patients. Twenty-six patients (84%) received neoadjuvant therapy followed by response evaluation. Median OS was 21 months [IQR 9-36] with 2- and 5-year survival rates of 43% and 30%, respectively. While disease recurred in 80% of patients (20 of 25 patients) after radical resection, patients with a solitary liver metastasis had a median OS of 34 months. The number of liver metastases was a prognostic factor for OS (solitary metastasis aHR 0.330; p-value = 0.025). Thirty-day mortality was zero and complications occurred in 55% of patients. Long-term survival can be achieved in well-selected patients who undergo surgical resection of the primary tumour and local treatment of synchronous liver metastases. In particular, patients with a solitary liver metastasis seem to have a favourable prognosis.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Suiza